StratDeck

Two stocks in Healthcare

argenx vs Ypsomed Holding: profit, growth, debt and price compared

argenx is stronger on 4 of 6 figures: profit margin, sales growth, debt and price for its expected profit. Ypsomed Holding is stronger on 1: price trend.

Figures as of 18 November 2026Yahoo Finance
Explore argenx's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

argenx and Ypsomed Holding side by side
argenxARGX.BRYpsomed HoldingYPSN.SW
Net marginStronger: 31.7%30.4%
Revenue growth, past yearStronger: +52.10%−13.30%
Debt to equityStronger: 0.6%34.9%
Forward P/EStronger: 26.9×28.8×
Dividend yield—1.04%
AnalystsBuy · 23Buy · 14
From its 200-day average+11.9%Stronger: +21.2%

Share price over the past year

  • argenx+9.4%
  • Ypsomed Holding+32.0%

24 Nov 202518 Nov 2026

argenx or Ypsomed Holding: which is stronger?

  • ARGX.BR

    Which is more profitable?

    argenx keeps more of each sale as profit: 31.7% against 30.4%.

  • ARGX.BR

    Which is growing its sales faster?

    argenx is growing its sales faster: +52.10% over the past year, against −13.30%.

  • ARGX.BR

    Which has borrowed less?

    argenx has borrowed less: its debt is 0.6% of what its shareholders own, against 34.9% for Ypsomed Holding.

  • ARGX.BR

    Which costs less for the profit it is expected to make?

    argenx costs less for the profit it is expected to make: 26.9× its forward earnings, against 28.8×.

  • Which pays more in dividends?

    Ypsomed Holding pays 1.04% a year in dividends for what a share costs, where argenx pays none.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • YPSN.SW

    Which is in the stronger price trend?

    Ypsomed Holding's price is in the stronger trend: 21.2% above its 200-day average, against 11.9% above.

What each company does

ARGX.BRargenx

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

Reports results on 25 February 2027

YPSN.SWYpsomed Holding

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally.

Reports results on 19 May 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.